Skip to content
Peptide research

Cerebrolysin

Also known as FPF-1070
Category
Brain & Cognition
Administration routes
Injectable
Regulatory status
Not FDA-approved

Cerebrolysin is a mix of small peptides and amino acids from pig brain protein, used for cognitive decline, stroke, and brain injury. Human evidence is uneven: Alzheimer benefit is well supported, injury and stroke recovery only moderately so, and neuroplasticity claims remain speculative. A 2023 Cochrane review found no stroke mortality benefit and a possible increase in non-fatal serious adverse events, and it is contraindicated in severe renal impairment and status epilepticus, with caution required in other seizure disorders. Not FDA-approved in the US.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Note: Cerebrolysin is not a single peptide but a complex mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine brain tissue. It contains thousands of peptide fragments under 10 kDa without a single defined amino acid sequence.

Cerebrolysin is a brain-derived peptide mixture obtained from purified pig brain proteins. It contains a blend of low-molecular-weight neuropeptides (about 25%) and free amino acids (about 75%) that can cross the blood-brain barrier. The peptide components mimic the activity of several natural brain growth factors including BDNF, GDNF, NGF, and CNTF. Manufactured by Ever Pharma in Austria, it is approved in many countries outside the US for stroke recovery, traumatic brain injury, and dementia.

How it works in the body

A mixture of small peptides and free amino acids derived from purified pig brain proteins. These fragments mimic natural neurotrophic factors (BDNF, GDNF, NGF, CNTF), activating the PI3K/Akt and MAPK/ERK pathways in neurons. This promotes nerve cell survival, new synapse formation, and neuroplasticity.

Research overview

Cerebrolysin works through multiple brain-protective mechanisms simultaneously. It boosts the production of key brain growth factors (VEGF, BDNF, IGF-1, NGF) while reducing inflammatory signals, and activates the Sonic Hedgehog signaling pathway involved in brain repair after stroke. At the cellular level, it supports new brain cell growth, blood vessel formation in the brain, nerve fiber branching and connection-building, and protective insulation (myelination) of nerve fibers. It also protects brain cells by reducing glutamate toxicity (a major cause of brain cell death after stroke), lowering oxidative stress, preventing programmed cell death, and stabilizing the blood-brain barrier. It has one of the larger clinical evidence bases among neuropeptides, with multiple randomized controlled trials in stroke, traumatic brain injury, and Alzheimer's disease — though results have been mixed and some meta-analyses have questioned the clinical significance of the benefits. It is not FDA-approved in the United States.

Who researches Cerebrolysin?

Commonly researched by

  • People exploring tissue repair and injury recovery

    Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

Important considerations for

  • Those with Epilepsy

    High

    Neurotrophic effects may lower seizure threshold. Use with caution in epilepsy.

  • Those with Severe renal impairment

    Moderate

    Contains amino acid fragments that require renal clearance.

  • Those who are pregnant or breastfeeding

    Absolute

    No reproductive safety data. Contains complex protein fragments.

Safety & interactions

Do not use if

  • Severe renal impairment

    Absolute

    Contains amino acid fragments that require renal clearance.

  • Epilepsy

    High

    Neurotrophic effects may lower seizure threshold. Use with caution in epilepsy.

General cautions

  • Pregnancy

    High

    Avoid during pregnancy unless clinically required. Animal reproductive studies found no evidence of reproductive toxicity; adequate human pregnancy safety is unestablished.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(9)

Rated by level of concern

  • Not FDA-approved — limited regulatory oversight in the US

    High

    FDA Drugs@FDA / Orange Book (no listing); manufacturer registration outside the US, https://www.cerebrolysin.com/

  • The 2023 Cochrane review found no mortality benefit and a possible increase in non-fatal serious adverse events after acute ischemic stroke.

    Moderate

    Ziganshina LE et al., Cochrane Database Syst Rev 2023, CD007026.pub7, PMID 37818733

  • Contraindicated in epilepsy — may lower seizure threshold

    Moderate

    Cerebrolysin Summary of Product Characteristics, manufacturer (https://www.cerebrolysin.com/)

  • Contraindicated in severe renal impairment.

    Moderate

    Cerebrolysin Summary of Product Characteristics (https://www.cerebrolysin.com/)

  • Contraindicated in hypersensitivity to porcine-derived biological products

    Moderate

    Cerebrolysin Summary of Product Characteristics (https://www.cerebrolysin.com/)

  • Common adverse effects: vertigo, agitation, feeling hot, headache, nausea, sweating (generally mild and transient)

    Low

    Strilciuc S et al., Pharmaceuticals (Basel) 2021, 12-RCT safety meta-analysis, PMC8708612; Panisset et al. 2002, PMID 12111446; Cerebrolysin SmPC

  • Porcine-derived product carries theoretical risk of allergic reactions or prion concerns (though no cases documented)

    Theoretical

    Manufacturer manufacturing/safety documentation (https://www.cerebrolysin.com/cerebrolysin/about-cerebrolysin)

  • Heterogeneous clinical evidence — stroke benefit remains controversial despite widespread international use

    High

    Cochrane CD007026.pub7, PMID 37818733 vs Cureus 2025 14-RCT meta-analysis, PMC12465088 — conflicting conclusions

  • Lack of standardization concerns: as a biological peptide mixture, batch-to-batch consistency may vary

    Low

    Manufacturer product composition documentation (https://www.cerebrolysin.com/)

Interaction summary(8)

Rated by direction with this peptide

  • MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid, selegiline)

    CautionLow

    Label-derived only: the SmPC advises against combining Cerebrolysin with MAO inhibitors in the same infusion and says concurrent use may require dose adjustment of the antidepressant. No clinically confirmed interaction (e.g. serotonin syndrome or hypertensive crisis) has been reported in trials or post-marketing; a 'monoaminergic modulation' mechanism is speculative.

    Cerebrolysin Summary of Product Characteristics (https://www.cerebrolysin.com/)

  • Antidepressants (SSRIs, tricyclics)

    CautionLow

    Labelling advises not mixing in the same infusion and supervising concurrent use because of possible additive CNS effects; no clinically confirmed adverse interaction has been reported in trials. Label-derived and theoretical.

    Cerebrolysin Summary of Product Characteristics (https://www.cerebrolysin.com/)

  • Balanced amino-acid infusion solutions and lipid/pH-altering infusion fluids

    CautionModerate

    A pharmaceutical incompatibility rather than a pharmacological one, and an explicit label prohibition: Cerebrolysin must not be mixed in the same infusion bottle with balanced amino-acid solutions or with solutions that alter pH or lipid content. Relevant only to parenteral administration by a clinician.

    Cerebrolysin Summary of Product Characteristics (https://www.cerebrolysin.com/)

  • Alteplase (rt-PA) thrombolysis in acute ischaemic stroke

    NeutralLow

    A prospective, randomized, double-blind, placebo-controlled trial (Lang et al., n=119) found combined rt-PA plus Cerebrolysin safe with no difference in safety parameters, but no improvement in overall disability at 90 days; the trial was stopped after an interim analysis showed no primary-outcome benefit. Safe to combine, benefit unproven.

    Lang W et al., Int J Stroke 2013;8(2):95-104, PMID 23009193

  • Cholinesterase inhibitors (donepezil) in Alzheimer disease

    SynergisticLow

    Qualified: a randomized controlled trial of Cerebrolysin (n=64) vs donepezil (n=66) vs both (n=67) in mild-to-moderate AD found the combination safe and numerically best on cognition, but the between-group cognitive differences were NOT statistically significant and there was no placebo arm. The 'synergy' rests mainly on a companion biomarker analysis showing a greater serum BDNF rise with the combination. Directionally supportive, clinically unproven.

    Alvarez XA et al., Curr Alzheimer Res 2011;8(5), PMID 21679156; Alvarez XA et al., Int J Neuropsychopharmacol 2016;19(6), PMID 27207906

  • Antiepileptic drugs / patients with a seizure disorder

    CautionModerate

    Cerebrolysin is contraindicated in epilepsy per the manufacturer's label on the grounds of possible increased seizure frequency, so it should not be added to an anticonvulsant regimen without specialist supervision. Rated Moderate because it reflects an absolute labelled contraindication, though the underlying human evidence is limited to labelling rather than reported events.

    Cerebrolysin Summary of Product Characteristics (https://www.cerebrolysin.com/)

  • Repetitive transcranial magnetic stimulation (rTMS) after TBI

    SynergisticLow

    A single-centre phase II randomized, double-blind, placebo-controlled trial in 93 patients with moderate-severe TBI compared Cerebrolysin plus rTMS against each alone and placebo, reporting greater functional and cognitive gains with the combination. One small trial only, not replicated.

    Front Neurosci 2023, PMC10285097

  • Standard post-stroke rehabilitation therapy

    SynergisticLow

    This combination has been tested in humans. The CARS trial (Cerebrolysin and Recovery After Stroke) was a prospective, randomized, double-blind, placebo-controlled multicentre study of Cerebrolysin added to standardized rehabilitation started 24-72 h after stroke, reporting improved motor function; a CARS-1/CARS-2 pooled analysis was concordant. It was manufacturer-sponsored and not confirmed on hard functional-independence endpoints.

    Muresanu DF et al., Stroke 2016;47:151-159, PMID 26564102

Known risks(9)

  • Not FDA-approved — limited regulatory oversight in the US

  • The 2023 Cochrane review found no mortality benefit and a possible increase in non-fatal serious adverse events after acute ischemic stroke.

  • Contraindicated in epilepsy — may lower seizure threshold

  • Contraindicated in severe renal impairment.

  • Contraindicated in hypersensitivity to porcine-derived biological products

  • Common adverse effects: vertigo, agitation, feeling hot, headache, nausea, sweating (generally mild and transient)

  • Porcine-derived product carries theoretical risk of allergic reactions or prion concerns (though no cases documented)

  • Heterogeneous clinical evidence — stroke benefit remains controversial despite widespread international use

  • Lack of standardization concerns: as a biological peptide mixture, batch-to-batch consistency may vary

Drug interactions(5)

  • tPA (tissue plasminogen activator)

    Safe in combination. Cerebrolysin may also stabilize BBB permeability disrupted by tPA. Studied in acute ischemic stroke.

  • Donepezil

    Combination of neurotrophic (Cerebrolysin) and cholinergic (donepezil) treatment was safe and effective in mild-to-moderate Alzheimer disease. May enhance overall efficacy.

  • Rivastigmine

    Safe in combination per clinical safety review. Both used for dementia indications.

  • MAO inhibitors

    Theoretical concern due to amino acid content. Manufacturer recommends caution with concurrent MAO inhibitor use.

  • Antiepileptic drugs

    Cerebrolysin is contraindicated in epilepsy. If used in patients on antiepileptics, close monitoring of seizure threshold is warranted.

Research & benefits

Evidence base

Evidence Level
Moderate
Total Studies
Over 200 clinical studies across stroke, TBI, and dementia indications
Human Studies
Thousands — meta-analyses include 2,202+ stroke patients (12 RCTs) and 8,749 TBI patients (10 studies)

Strongest evidence for mild-to-moderate Alzheimer disease (6 RCTs, significant cognitive and global benefits). Promising but heterogeneous evidence for TBI (significant GOS improvement). Mixed evidence for acute ischemic stroke — a 2023 Cochrane review found no benefit for preventing all-cause mortality. Approved in 45+ countries based on available evidence.

Researched for(6)

Rated by confidence in the evidence

  • Neuroprotection after acute brain injury

    Medium

    Human stroke and TBI trials show no clear survival benefit; strong animal neuroprotection data only.

    Ziganshina LE et al., Cochrane Database Syst Rev 2023, CD007026.pub7, PMID 37818733; Cureus 2025, 14-RCT meta-analysis, PMC12465088; Poon W et al., CAPTAIN I, Neurol Sci 2020, PMID 31494820

  • Neuroplasticity enhancement

    Low

    Strong animal evidence for enhanced plasticity; human data limited to indirect cognitive and BDNF signals.

    Alvarez XA et al., 'Synergistic increase of serum BDNF in Alzheimer patients treated with cerebrolysin and donepezil', Int J Neuropsychopharmacol 2016;19(6), PMID 27207906

  • Cognitive improvement in Alzheimer disease

    High

    Multiple placebo-controlled human trials show modest cognitive and global benefit, mostly short term.

    Panisset et al., J Neural Transm 2002, PMID 12111446; Gauthier S et al., Dement Geriatr Cogn Disord 2015, PMID 25832905

  • Functional recovery in traumatic brain injury

    Medium

    Two small placebo-controlled TBI trials show mixed results using non-standard composite outcome measures.

    Poon W et al., CAPTAIN I, Neurol Sci 2020, PMID 31494820; Muresanu DF et al., CAPTAIN II, Neurol Sci 2020, PMID 31897941

  • Neurotrophic factor modulation

    Low

    Preclinical mimics of BDNF and NGF signaling; only one human trial shows a serum BDNF increase.

    Alvarez XA et al., Int J Neuropsychopharmacol 2016;19(6), PMID 27207906

  • Blood-brain barrier stabilization

    Low

    Animal studies show reduced blood-brain barrier leakage after injury; no human permeability data exist.

    Sharma HS et al., Ann N Y Acad Sci 2010, PMID 20633118; Sharma HS et al., Acta Neurochir Suppl 2010, PMID 19812972

Benefits(6)

  • Neuroprotection after acute brain injury

  • Neuroplasticity enhancement

  • Cognitive improvement in Alzheimer disease

  • Functional recovery in traumatic brain injury

  • Neurotrophic factor modulation

  • Blood-brain barrier stabilization

Key studies(5)

  1. Gauthier S, Proano JV, Jia J, Froelich L, Vester JC, Doppler E

    Dementia and Geriatric Cognitive Disorders

    2015

    Meta-analysis of 6 RCTs comparing Cerebrolysin 30 mL/day with placebo. At 4 weeks, Cerebrolysin significantly improved cognitive function (SMD -0.40, 95% CI -0.66 to -0.13, p=0.003) and global clinical change (OR 3.32, 95% CI 1.20-9.21, p=0.02). Benefits persisted at 6 months for global measures. Safety comparable to placebo.

  2. Jarosz K, Kojder K, Andrzejewska A, Solek-Pastuszka J, Jurczak A

    Brain Sciences

    2023

    Systematic review of 10 studies (8,749 TBI patients). Cerebrolysin associated with statistically significant improvement in Glasgow Outcome Scale (DM=0.422, 95% CI 0.262-0.581, p<0.001). Positive but non-significant trend in GCS improvement. Minimal adverse events reported across studies.

  3. Thome J, Doppler E

    Drugs Today (Barcelona)

    2012

    Comprehensive safety review: incidence of adverse events similar in Cerebrolysin and placebo groups. Most common AEs were vertigo, agitation, and feeling hot, all generally mild and transient. Safe in combination with tPA and cholinesterase inhibitors (donepezil, rivastigmine). No major changes in vital signs or laboratory parameters.

  4. Multiple authors

    Pharmaceuticals

    2021

    Pooled safety data from 2,202 patients in 12 RCTs. Differences in mortality, adverse events, serious adverse events, and non-fatal serious adverse events were not statistically significant. This was a safety analysis, not an assessment establishing stroke efficacy.

  5. Rejdak K, et al.

    Medicinal Research Reviews

    2023

    Comprehensive review of Cerebrolysin mechanisms: modulates NTF and Shh signaling pathways, regulates neurogenesis, angiogenesis, dendrite arborization, axonal sprouting, myelination, and neurovascular unit remodeling.

What research suggests over time

  • Weeks 2-4

    International clinical use

    Early cognitive shifts reported in Alzheimer's and stroke recovery patients during IV infusion treatment.

  • Week 4

    Meta-analysis (Dement Geriatr 2015)

    Cognitive function improvement (SMD -0.40, 95% CI -0.66 to -0.13) in mild-to-moderate Alzheimer's disease across 6 RCTs.

  • Long-term

    International clinical use

    Glasgow Outcome Scale improvement in TBI patients across 10 systematic-review studies (n=8,749, Brain Sci 2023). Approved in 45+ countries; not FDA-approved.

Regulation & availability

Why researchers look at it

One of the few neuropeptide therapies with 200+ clinical studies, regulatory approval in 45+ countries, and six RCTs showing significant cognitive benefits in mild-to-moderate Alzheimer's — plus TBI meta-analyses covering 8,749 patients demonstrating improved outcomes. A 2023 Cochrane review found no benefit for preventing mortality in acute ischemic stroke, tempering some earlier claims. It remains unapproved in the US with no current path to FDA approval without new large-scale Phase III trials.

Estimated cost
$100-300/mo (available OTC in some countries)
FDA status
NOT FDA-approved for any indication. No FDA approval application pending as of 2026. Approved in 45+ countries for stroke, TBI, and dementia. The FDA substance registration (UNII: 37KZM6S21G) exists for identification purposes only. Cochrane reviews have questioned efficacy for acute ischemic stroke. No current path to US approval without new large-scale Phase III RCTs.
WADA status
Cerebrolysin is not named. S0 depends on absence of any governmental human therapeutic approval, not local approval. Its foreign authorizations preclude that rationale; confirm other applicable rules.
Prescribability
Not FDA-approved in the United States. Available by prescription in over 45 countries including Austria, Germany, Russia, China, South Korea, and other European and Asian nations. Administered via intravenous or intramuscular injection by healthcare providers.
Availability
Prescription medication in 45+ countries with national authorization (Austria, Germany, Russia, China, South Korea, and others); not FDA-approved or available as an approved US prescription product. Administered intravenously or intramuscularly in clinical settings. US clinical investigation generally requires an IND in effect as well as IRB approval and informed consent; IRB approval alone does not authorize access.

International status

  • EU

    Approved in Austria, Germany, and several EU countries

  • US

    Not FDA-approved

  • China

    Approved for vascular dementia and stroke recovery

  • Japan

    Not approved

  • Russia

    Approved and widely used for stroke, TBI, dementia

Regulatory timeline(10)

  1. 1970s
    DevelopmentCerebrolysin developed by EBEWE Pharma (now Ever Pharma) in Austria through enzymatic proteolysis of porcine brain proteins.
  2. 1980s-1990s
    International approvalsApproved in multiple European and Asian countries for stroke, TBI, and dementia indications. Became widely used in Russia, China, and Central/Eastern Europe.
  3. 2007
    Major AD trialLarge randomized controlled trial of Cerebrolysin in Alzheimer disease published, contributing to evidence base.
  4. 2012
    Comprehensive safety reviewThome & Doppler published safety profile review pooling data from dementia and stroke clinical trials (PMID: 22514795).
  5. 2015
    AD meta-analysisGauthier et al. published meta-analysis of 6 RCTs confirming efficacy in mild-to-moderate AD (PMID: 25832905).
  6. 2019
    Cochrane vascular dementia reviewCochrane review of Cerebrolysin for vascular dementia published (PMID: 31710397).
  7. 2021
    Stroke safety meta-analysisSafety meta-analysis of 12 RCTs, involving 2,202 patients, found no statistically significant differences from placebo in the analyzed safety outcomes.
  8. 2023
    TBI meta-analysis and mechanism reviewMajor systematic review in TBI (8,749 patients) showed significant GOS improvement. Rejdak et al. published comprehensive mechanism review in Med Res Rev.
  9. 2025
    Ongoing researchCerebrolysin post-TBI recovery pharmacology and clinical evidence review published (ScienceDirect). Vascular dementia management role explored.
  10. 2026
    Current statusRemains unapproved by FDA. No US approval application pending. Continues to be prescribed in 45+ countries. Active registry studies (CREGS-S, NCT02541227) ongoing.

Sources & FAQs

Research sources(10)

Frequently asked questions(6)

What is Cerebrolysin made of?

Cerebrolysin is produced by standardized enzymatic proteolysis of lipid-free porcine (pig) brain proteins. The resulting preparation contains approximately 25% low-molecular-weight neuropeptides and 75% free amino acids. The peptide fraction includes fragments with neurotrophic activity similar to BDNF, GDNF, NGF, and CNTF.

Is Cerebrolysin FDA-approved?

No. As of 2026, Cerebrolysin is not FDA-approved in the United States for any indication. It is approved in over 45 countries (including Austria, Germany, Russia, China, South Korea) for stroke, traumatic brain injury, and dementia.

How is Cerebrolysin administered?

Cerebrolysin is given by injection only — either intravenous (IV) infusion or intramuscular (IM) injection. It is not available in oral form. The peptides must be delivered parenterally to maintain bioactivity and cross the blood-brain barrier.

What conditions is Cerebrolysin used for?

Primary indications include acute ischemic stroke, traumatic brain injury (TBI), Alzheimer disease, vascular dementia, and other neurodegenerative conditions. The strongest clinical evidence supports its use in mild-to-moderate Alzheimer disease.

Is Cerebrolysin safe?

Clinical trials show a safety profile comparable to placebo. Most common adverse events are mild and transient: vertigo, agitation, feeling hot, headache, nausea, and sweating. However, it is not recommended for people with epilepsy, kidney disease, or hypersensitivity to constituents. A Cochrane review raised concerns about possible higher hospitalization rates in stroke patients.

Can Cerebrolysin be combined with other drugs?

Studies support safe combination with tPA (tissue plasminogen activator) for stroke and cholinesterase inhibitors (donepezil, rivastigmine) for dementia. Combination with donepezil showed comparable or enhanced efficacy in Alzheimer disease.